TrialBlood advances2020
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Mark A Schroeder et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
57 papers cite it
this paperpooled ittrialcites it